Baird on Gilead Sciences (GILD): 'Incrementally positive on clinical data'
Tweet Send to a Friend
Baird analyst Brian Skorney reiterated a Neutral rating and $80.00 price target on Gilead Sciences (NASDAQ: GILD).The analyst comments "We ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
